Descripción de la empresa
Ginkgo Bioworks Holdings, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it develops a proprietary platform for cell engineering in the United States. The company executes its operations through two primary segments: Cell Engineering and Biosecurity, offering specialized research and development solutions alongside essential cell engineering tools to its client base. This biotechnology entity maintains a workforce of 485 employees and holds a total market capitalization of $422.32M, reflecting its current valuation in the public markets. While the company generates annual revenue of $170.16M, this figure, combined with a market cap of $422.32M, suggests a valuation that is significantly higher than its trailing twelve-month sales, indicating a market premium often associated with high-growth potential or specific strategic assets in the biotech space.
Salud financiera
The financial performance of Ginkgo Bioworks is characterized by a trailing twelve-month revenue of $170.16M and a net income of $-312,763,008, while the EBITDA stands at $-267,822,000. The substantial disparity between the positive revenue of $170.16M and the deep net loss reveals a cost structure where operating expenses heavily outweigh gross profits, resulting in a net loss nearly double the magnitude of the reported EBITDA. Free cash flow for the period is reported at $-72,883,000, which indicates a consumption of cash that limits the company's immediate financial flexibility for capital expenditures or strategic acquisitions without external financing. The gross margin stands at 72.4%, suggesting strong pricing power or efficient production costs on the core product, yet this is counterbalanced by an operating margin of -209.7% and a profit margin of -183.8%, highlighting severe inefficiencies or high overhead costs in the operating structure. The balance sheet shows a cash position of $422.62M against total debt of $439.88M, with a debt-to-equity ratio of 86.49, indicating a highly leveraged financial structure where liabilities approach liquidity levels. Despite the high leverage, the current ratio is 4.92, which signals robust short-term liquidity and an ability to cover current liabilities with current assets more than four times over. Return on Equity is -51.1% and Return on Assets is -15.4%, metrics that collectively reveal that management is currently destroying shareholder value and utilizing assets to generate losses rather than returns.
Evaluación de valoración
Valuation multiples for Ginkgo Bioworks present a complex picture, with a P/E Ratio (TTM) listed as N/A due to the lack of positive earnings, and a Forward P/E of -1.88. The divergence between a nonexistent trailing P/E and a negative forward P/E implies that the market is pricing in a potential earnings recovery or turnaround, though the negative forward multiple currently reflects anticipated continued losses or a specific accounting adjustment for future periods. The price-to-book ratio is 0.78, indicating that the company trades at a discount to its net asset value, which is relatively rare for a technology-focused biotech firm and suggests the market is undervaluing its intangible assets or intellectual property. Alternative valuation metrics further illustrate the company's position, with a price-to-sales ratio of 2.48 and an EV/EBITDA of -1.55, suggesting that investors are valuing the business primarily on its revenue generation capabilities rather than profitability. The stock has exhibited significant volatility over the last year, trading between a 52-week high of $17.58 and a 52-week low of $5.37. Without the current share price explicitly provided in the facts, the range itself demonstrates a trading span of over 200%, while a beta of 1.57 indicates that the stock's price volatility is significantly higher than the broader market, moving 57% more aggressively than the index in response to market movements.
Growth & Income
Revenue growth year-over-year stands at -23.8%, while earnings growth is N/A due to the absence of positive earnings in the previous period. The contraction in revenue combined with negative earnings growth highlights a challenging operational environment where top-line decline is not being offset by cost reductions to improve profitability. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders, opting instead to retain all capital internally to fund research and development or to service its existing debt obligations. This retention strategy is typical for biotechnology firms in development stages, yet the negative growth trajectory complicates the ability to fund expansion solely through internal cash flows. Overall, the growth and income profile of Ginkgo Bioworks is defined by negative revenue expansion and a complete reliance on external capital markets or cash reserves to sustain operations, as evidenced by the negative free cash flow and lack of dividend distributions.